Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury.

Taquet M. et al, (2024), Brain Commun, 6

Balancing the value and risk of exercise-based therapy post-COVID-19: a narrative review.

Singh SJ. et al, (2023), Eur Respir Rev, 32

Synbiotics in post-acute COVID-19 syndrome-a potential new treatment framework?

Raman B. and Ramasamy MN., (2023), Lancet Infect Dis

Long COVID research: an update from the PHOSP-COVID Scientific Summit.

Brightling CE. et al, (2023), Lancet Respir Med, 11, e93 - e94

Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study.

C-MORE/PHOSP-COVID Collaborative Group None., (2023), Lancet Respir Med, 11, 1003 - 1019

Personalizing Apical Hypertrophic Cardiomyopathy Diagnosis: A Major Step Forward, but Challenges Remain.

Raman B., (2023), JACC Cardiovasc Imaging

Erratum for: Lung Abnormalities Detected with Hyperpolarized 129Xe MRI in Patients with Long COVID.

Grist JT. et al, (2023), Radiology, 309

Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization.

Taquet M. et al, (2023), Nat Med

Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy.

Farrant J. et al, (2023), Heart, 109, 1175 - 1182

Mechanisms and prognostic impact of myocardial ischaemia in hypertrophic cardiomyopathy.

Coleman JA. et al, (2023), International Journal of Cardiovascular Imaging, 1 - 18

Liver disease is a significant risk factor for cardiovascular outcomes - A UK Biobank study.

Roca-Fernandez A. et al, (2023), J Hepatol

Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls.

Zheng B. et al, (2023), Lancet Reg Health Eur, 29

Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.

Hundertmark MJ. et al, (2023), Circulation, 147, 1654 - 1669

Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID)

Elneima O. et al, (2023)

Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study.

Finnigan LEM. et al, (2023), EClinicalMedicine, 59

Novel insights into diminished cardiac reserve in non-obstructive hypertrophic cardiomyopathy from four-dimensional flow cardiac magnetic resonance component analysis.

Ashkir Z. et al, (2023), Eur Heart J Cardiovasc Imaging

Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study.

Jackson C. et al, (2023), Lancet Respir Med

3-Dimensional Strain Analysis of Hypertrophic Cardiomyopathy: Insights From the NHLBI International HCM Registry.

Heydari B. et al, (2023), JACC Cardiovasc Imaging, 16, 478 - 491

Acute changes in myocardial tissue characteristics during hospitalization in patients with COVID-19.

Shanmuganathan M. et al, (2023), Front Cardiovasc Med, 10

Characteristics and risk factors for post-COVID-19 breathlessness after hospitalisation for COVID-19.

Daines L. et al, (2023), ERJ Open Res, 9

Load More

Include forthcoming?